Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is Wall Street Bullish or Bearish on Regeneron Pharmaceuticals Stock?

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company has a market capitalization of $83.7 billion and develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases, as well as cancer and more.

The company's shares have outperformed the broader market over the past year and in 2026. REGN stock has surged 14.1% over the past 52 weeks and 1.4% on a YTD basis. In comparison, the S&P 500 Index ($SPX) has returned 11.7% over the past year and grown marginally in 2026.

Fundamentals

See More
  • Market Capitalization, $K 82,713,216
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,578 M
  • EBITDA $ 4,122 M
  • 60-Month Beta 0.40
  • Price/Sales 5.84
  • Price/Cash Flow 18.87
  • Price/Book 2.68

Options Overview Details

View History
  • Implied Volatility 34.71% (-0.04%)
  • Historical Volatility 26.52%
  • IV Percentile 37%
  • IV Rank 25.14%
  • IV High 60.01% on 04/08/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 7) 24.44 (3.15%)
  • Put/Call Vol Ratio 0.99
  • Today's Volume 368
  • Volume Avg (30-Day) 1,818
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 48,067
  • Open Int (30-Day) 45,788
  • Expected Range 751.04 to 799.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 5.96
  • Number of Estimates 6
  • High Estimate 8.00
  • Low Estimate 4.29
  • Prior Year 6.43
  • Growth Rate Est. (year over year) -7.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
731.51 +5.71%
on 02/02/26
815.00 -5.12%
on 02/17/26
+39.48 (+5.38%)
since 01/20/26
3-Month
691.86 +11.77%
on 12/09/25
821.11 -5.83%
on 01/09/26
+36.26 (+4.92%)
since 11/20/25
52-Week
476.49 +62.28%
on 06/05/25
821.11 -5.83%
on 01/09/26
+77.24 (+11.10%)
since 02/20/25

Most Recent Stories

More News
Is Wall Street Bullish or Bearish on Regeneron Pharmaceuticals Stock?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and analysts remain highly upbeat about the stock’s growth potential.

XLV : 156.66 (-0.38%)
$SPX : 6,901.73 (+0.58%)
REGN : 776.96 (-0.57%)
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability  If approved,...

REGN : 776.96 (-0.57%)
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges

1 Healthcare Stock Worth Your Attention and 2 Facing Challenges

ILMN : 117.93 (-1.72%)
MOH : 147.09 (-0.78%)
REGN : 776.96 (-0.57%)
Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:  REGN ) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference...

REGN : 776.96 (-0.57%)
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies ...

REGN : 776.96 (-0.57%)
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis...

REGN : 776.96 (-0.57%)
Regeneron: Q4 Earnings Snapshot

Regeneron: Q4 Earnings Snapshot

REGN : 776.96 (-0.57%)
Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025

Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025

REGN : 776.96 (-0.57%)
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024 Fourth quarter 2025 Dupixent ® global...

REGN : 776.96 (-0.57%)
Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow

Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow

REGN : 776.96 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 807.17
2nd Resistance Point 798.59
1st Resistance Point 790.48
Last Price 776.96
1st Support Level 773.79
2nd Support Level 765.21
3rd Support Level 757.10

See More

52-Week High 821.11
Last Price 776.96
Fibonacci 61.8% 689.46
Fibonacci 50% 648.80
Fibonacci 38.2% 608.13
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar